Pfizer Pipeline
Pfizer Pipeline Snapshot 4 Pipeline represents progress of R&D programs as of January 31, 2017 Included are 62 NMEs, 26 additional indications, plus 8 biosimilars
Download Pfizer Pipeline
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
NARDIL - Pfizer
www.pfizer.com1 NARDIL® (Phenelzine Sulfate Tablets, USP) Suicidality and Antidepressant Drugs Antidepressants increased the risk compared to placebo of suicidal thinking and behavior
MATERIAL SAFETY DATA SHEET - Pfizer
www.pfizer.commaterial safety data sheet _____ 5. fire fighting measures
Sheet, Data, Safety, Material, Material safety data sheet, Pfizer
MATERIAL SAFETY DATA SHEET - Pfizer
www.pfizer.commaterial safety data sheet _____ 7. handling and storage
Sheet, Data, Safety, Material, Material safety data sheet, Pfizer
MATERIAL SAFETY DATA SHEET - Pfizer
www.pfizer.comMATERIAL SAFETY DATA SHEET _____ Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so.
Sheet, Data, Safety, Material, Material safety data sheet, Pfizer
PFIZER FACTS The Burden of Cancer in Asia
www.pfizer.comTheburdenofcancerinAsia I n2002,4.2millionnewcancercases—39%ofnewcasesworldwide—werediagnosedamong …
MATERIAL SAFETY DATA SHEET - Pfizer
www.pfizer.commaterial safety data sheet _____ 2. hazards identification
Sheet, Data, Safety, Material, Material safety data sheet, Pfizer
USPI medroxyprogesterone acetate - Depo …
www.pfizer.com1 Depo-Provera® medroxyprogesterone acetate injectable suspension, USP DESCRIPTION DEPO-PROVERA Sterile Aqueous Suspension contains medroxyprogesterone acetate,
Acetate, Uspi medroxyprogesterone acetate depo, Uspi, Medroxyprogesterone, Depo, Medroxyprogesterone acetate
Patient Information About - Pfizer
www.pfizer.comPatient Information About depo-subQ provera 104™ medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD
Information, Patients, About, Pfizer, Depo, Patient information about, Patient information about depo
Pfizer Inc 100 Route 206 North Peapack, NJ 07977 …
www.pfizer.comApril 13, 2015 Pfizer Inc 100 Route 206 North Peapack, NJ 07977 Email: pfizerinjectables@pfizer.com Global Established Pharmaceuticals Depo®-Testosterone (testosterone cypionate injection, USP) CIII
Pharmaceutical, Global, Email, North, Pfizer, Established, Depo, North peapack, Peapack, Nj 07977, 07977, Nj 07977 email, Com global established pharmaceuticals depo
2. HAZARDS IDENTIFICATION - Pfizer
www.pfizer.com1. PRODUCT AND COMPANY IDENTIFICATION Product Name Chapstick Products Common Name Not applicable Chemical Name Not applicable Synonyms ChapStick Classic, ChapStick Lip Moisturizer, ChapStick Medicated, ChapStick Flava-Craze,
Related documents
Bios of panelists for data science 050217 - Rutgers …
ijobs.rutgers.edudisorders.(He(published(these(findings(in(aco2firstauthor(manuscriptin(Neuron,which(combined(with(work(from(others(in(the(lab(reclassified(these(human(disorders.((Jigar
Fortune.com - Fortune 500: Full List 1-100 - Tom …
tomweston.netFortune.com - Fortune 500: Full List 1-100 http://www.fortune.com/fortune/subs/fortune500/top500/0,23613,,00.html 1 of 4 11/27/2005 3:58 PM · Try 3 Issues Free
Strategic Analysis of the Pharma Market, Future …
www.fgcasal.orgStrategic Analysis of the Pharma Market, Future Revenue Models and Key Players 2 “Personalised medicine is a laudable aim, but we are not anywhere near there yet…
Analysis, Strategic, Market, Pharma, Strategic analysis of the pharma market
PHARMA M&A REPORT 2018 - kurmannpartners.com
www.kurmannpartners.com6 YEAR 2017 IN REVIEW J& Shortly after Merck’s announcement, Pfizer informed that they are seeking a buyer for their consumer health business.
TaiGenBiopharmaceuticals Holdings Ltd. F*太 …
www.taigenbiotech.comA Research-Driven and Product Focus Company. An approved product A high value pipeline A productive R&D platform. Restricted & Confidential. 3
ANNUAL REPORT 2017 - viforpharma.com
www.viforpharma.comVifor Pharma Ltd. Annual Report 2017 3 172 02 2017 at a glance 03 Table of contents 04 Ee ivexcut maegsse 08 Highlighs t 10 Our vision, mission and strategy 14 Perorf manceoeervwi v 18 Key medium-term growth drivers and products 20 – aferect In®j ®/ect nFerj i 26 – Vifor Fresenius Medical Care Renal Pharma 30 – Veltassa® 32 – eivsect …
English short version ANNUAL REPORT 2017
www.viforpharma.com4 36 Vifor Pharma Ltd. Annual Report 2017 ExECUTiVE MESSAGE 172 ExECUT iVE CHA iRMAN Dear Shareholder, It is with great pleasure that I deliver my message as Executive Chairman for the first time following the